Supernus Pharmaceuticals, Inc.· SUPN
🇺🇸 US · MidSP600NASDAQ
- Price
- $43.25
- Day
- -5.98%
- Mkt Cap
- $2.51B
- 52W Range
- $36.46 – $59.68
- Volume
- 3.04M
- Beta
- 0.56
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.
Read full article
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) PR Newsw
Read full article
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read full article
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.54 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.91 per share a year ago.
Read full article
Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock merger that would create a company with about $2.2 billion in annual revenue and a portfolio of medicines for neurological, psychiatric and addiction-related conditions.
Read full article
MILWAUKEE, Aug. 3, 2026 /PRNewswire/ -- Ademi LLP is investigating Supernus (Nasdaq: SUPN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Indivior Pharmaceuticals. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
Read full article
NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) related to its sale to Indivior Pharmaceuticals, Inc. Under the terms of the proposed transaction, Supernus shareholders are expected to receive 1.5401 common shares of Indivior for each share of Supernus.
Read full article
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Read full article
Supernus Pharmaceuticals NASDAQ: SUPN and Indivior Pharmaceuticals announced a proposed all-stock, tax-free merger of equals that would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing 12-month net revenue as of June 30, 2026.
Read full article
Supernus Pharmaceuticals, Inc. (SUPN) M&A Call Transcript
Read full article
Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 3, 2026
Read full article
Supernus Pharmaceuticals (SUPN) has seen its stock rise following the announcement of an all-stock merger with Indivior (INDV). This strategic move comes alongs
Read full article